The population-attributable fraction for time-dependent exposures and competing risks-A discussion on estimands.

competing risks hospital-acquired infection mortality population-attributable risk time-dependent exposure

Journal

Statistics in medicine
ISSN: 1097-0258
Titre abrégé: Stat Med
Pays: England
ID NLM: 8215016

Informations de publication

Date de publication:
10 09 2019
Historique:
received: 22 05 2018
revised: 02 05 2019
accepted: 03 05 2019
pubmed: 5 6 2019
medline: 18 12 2020
entrez: 5 6 2019
Statut: ppublish

Résumé

The population-attributable fraction (PAF) quantifies the public health impact of a harmful exposure. Despite being a measure of significant importance, an estimand accommodating complicated time-to-event data is not clearly defined. We discuss current estimands of the PAF used to quantify the public health impact of an internal time-dependent exposure for data subject to competing outcomes. To overcome some limitations, we proposed a novel estimand that is based on dynamic prediction by landmarking. In a profound simulation study, we discuss interpretation and performance of the various estimands and their estimators. The methods are applied to a large French database to estimate the health impact of ventilator-associated pneumonia for patients in intensive care.

Identifiants

pubmed: 31162706
doi: 10.1002/sim.8208
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3880-3895

Informations de copyright

© 2019 John Wiley & Sons, Ltd.

Auteurs

Maja von Cube (M)

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Freiburg Center for Data Analysis and Modelling, University of Freiburg, Freiburg, Germany.

Martin Schumacher (M)

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Freiburg Center for Data Analysis and Modelling, University of Freiburg, Freiburg, Germany.

Sébastien Bailly (S)

HP2 Laboratory, University of Grenoble Alpes, Grenoble, France.
Department of Physiology and Sleep, Grenoble Alpes University Hospital, Grenoble, France.

Jean-François Timsit (JF)

UMR 1137 IAME Inserm, Université Paris Diderot, Paris, France.
APHP Medical and Infectious Diseases ICU, Bichat Hospital, Paris, France.

Alain Lepape (A)

Clinical Research Unit, Critical Care, Lyon Sud University Hospital, Hospices Civils de Lyon, Lyon, France.
Laboratory of Emerging Pathogens, International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France.

Anne Savey (A)

CPIAS Auvergne-Rhône-Alpes, Hospices Civils de Lyon, Lyon, France.
Laboratory of Emerging Pathogens, International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France.

Anais Machut (A)

CPIAS Auvergne-Rhône-Alpes, Hospices Civils de Lyon, Lyon, France.

Martin Wolkewitz (M)

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Freiburg Center for Data Analysis and Modelling, University of Freiburg, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH